Given at higher doses than in diabetes treatment, GLP-1 analogues are now routinely licensed for the treatment of obesity, for example high-dose Liraglutide 3 mg daily (43) and Semaglutide 2.4 mg weekly (44)
The first 24 hours After subcutaneous injection, the medication begins absorbing from the injection site into your bloodstream
Researchers may compare its triple-receptor agonist profile with single- or dual-receptor agonist profiles to better understand differences in receptor activation, intracellular signaling, and physiological responses
Achieving a stable and euthyroid (normal thyroid function) state is important because untreated or undertreated hypothyroidism can blunt the metabolic benefits of GLP-1 medications, such as weight loss and improved blood sugar control
Funding This work is funded by KBRI (25-BR-02-01, 25-BR-05-01), the Ministry of Trade, Industry and Energy (RS-2024-00507932), and by the Ministry of Science and ICT (2022R1A5A202954611 and RS-2025-16065563)
